Market Place
Sourcing Support
Merck Signs Agreement with Dr. Falk Pharma GmbH for MK-8690
04 Nov 2025 //
PRESS RELEASE
Merck Foundation Launches $22M to Improve Cardiovascular Care
03 Nov 2025 //
BUSINESS WIRE
Merck Reveals Q3 2025 Financial Results
30 Oct 2025 //
BUSINESSWIRE
Merck`s Pneumococcal Shot Capvaxive Off To `Very Strong Start`
30 Oct 2025 //
FIERCE PHARMA
EC Approves Keytruda Combo for PD-L1+Resectable Head&Neck Cancer
29 Oct 2025 //
BUSINESSWIRE
Merck, Eisai End Keytruda-Lenvima Collaboration In Liver Cancer
29 Oct 2025 //
FIERCE PHARMA
Welireg`s RCC Wins Could Pad Merck`s Post-Keytruda Sales
28 Oct 2025 //
FIERCE PHARMA
Merck Nabs updated FDA label for PAH med Winrevair
27 Oct 2025 //
BUSINESSWIRE
FDA Prioritizes KEYTRUDA And KEYTRUDA QLEX Combo with Padcev
23 Oct 2025 //
BUSINESSWIRE
Merck To Unveil Cardio-Pulmonary Pipeline Data At AHA Conference
23 Oct 2025 //
BUSINESSWIRE
Keytruda, Lenvima Show Long-Term Survival Benefit in Cancer
22 Oct 2025 //
INDPHARMAPOST
KEYTRUDA® Shows Prolonged Survival Benefit In Some NSCLC Patients
20 Oct 2025 //
BUSINESSWIRE
Immunos Therapeutics Shows IOS-1002 Promise In Advanced Solid
20 Oct 2025 //
PHARMIWEB
Merck Grows More Ambitious About `Workhorse` TROP2 ADC
20 Oct 2025 //
FIERCE PHARMA
Merck Grows Again In Va. With $3B Small-Molecule Drug Plant
20 Oct 2025 //
FIERCE PHARMA
ESMO: Daiichi, Merck Move Ovarian Cancer ADC Toward Pivotal Test
20 Oct 2025 //
FIERCE BIOTECH
AZ Faces FDA Challenge As Imfinzi-Lynparza Miss Survival Goal
19 Oct 2025 //
FIERCE PHARMA
Keytruda and Lenvima Show Long-Term Survival Benefit
18 Oct 2025 //
BUSINESSWIRE
Keytruda, Padcev Cut Risk Of Death By 50% In MIBC Patient Subset
18 Oct 2025 //
FIERCE PHARMA
Merck`s KEYNOTE-B96 Phase 3 Trial Meets Secondary Endpoint
16 Oct 2025 //
BUSINESSWIRE
In Ovarian Cancer, Keytruda Follows PFS Win With Survival Showing
16 Oct 2025 //
FIERCE PHARMA
Merck Reports Ph3 HIV Data for Oral DOR/ISL Combination Drug
15 Oct 2025 //
PHARMIWEB
Moderna Claims Early Victory For Cancer Antigen In Melanoma
13 Oct 2025 //
BIOSPACE
Merck Expands Keytruda`s Role In Cancer Innovation To New Tumor
11 Oct 2025 //
INDPHARMAPOST
Merck To Unveil HIV Pipeline Data At European AIDS Conf 2025
09 Oct 2025 //
PHARMIWEB
Merck Advances Oncology Innovation At ESMO 2025
09 Oct 2025 //
PHARMIWEB
Immutep Shares Update on Ph3 TACTI-004 Trial in Lung Cancer
09 Oct 2025 //
GLOBENEWSWIRE
Bioinvent Starts BI-1206 Ph 2a Trial In Advanced NSCLC & Melanoma
08 Oct 2025 //
PR NEWSWIRE
Merck Completes Acquisition Of Verona Pharma
07 Oct 2025 //
PRESS RELEASE
Merck Plans Q3 2025 Sales & Earnings Call On Oct. 30
01 Oct 2025 //
BUSINESSWIRE
Merck Releases Results from Successful Trial of Winrevair
01 Oct 2025 //
FIERCE PHARMA
Merck Opts in on Evaxian`s Preclinical Vaccine Candidate
25 Sep 2025 //
FIERCE BIOTECH
Merck Inks $349M Biobucks Deal to Apply AI to Tricky Targets
24 Sep 2025 //
FIERCE BIOTECH
Variational AI Enters Collaboration with MercK for Drug Discovery
23 Sep 2025 //
BUSINESSWIRE
Kennedy Targets Childhood Vaccines, History of Merck`s ProQuad
23 Sep 2025 //
BIOSPACE
LifeSpan Portfolio Co. Remedium Inks Landmark Deal with Eli Lilly
23 Sep 2025 //
PR NEWSWIRE
Study: One-Third of Trial Data May Be Unnecessary
19 Sep 2025 //
FIERCE BIOTECH
Merck Gets Positive CHMP Opinion for Enflonsia in RSV Prevention
19 Sep 2025 //
PHARMAWEB
FDA Approves Merck`s Injectable Version of Blockbuster Keytruda
19 Sep 2025 //
REUTERS
Merck, St. Louis Cardinals Pitch Heart Disease Awareness Push
17 Sep 2025 //
FIERCE PHARMA
UK Lawmakers Question Pharma Execs Over R&D Pullback
16 Sep 2025 //
FIERCE BIOTECH
FDA Grants Breakthrough Tag to Raludotatug Deruxtecan in CDH6
15 Sep 2025 //
BUSINESSWIRE
Merck touts Capvaxive`s potential to provide protection for kids
11 Sep 2025 //
FIERCE PHARMA
Merck Scraps £1 B Project, Along with All R&d Operations in UK
10 Sep 2025 //
FIERCE BIOTECH
Daiichi, Merck Prepare for Swift Approval Filing
07 Sep 2025 //
FIERCE BIOTECH
Merck Names David Weinreich Global R&D Head and Healthcare CMO
03 Sep 2025 //
INDPHARMAPOST
Merck`s Cholesterol Drug Gets a Boost with Another LateTrial
03 Sep 2025 //
PRESS RELEASE
Merck, Bayer`s Verquvo Records Puzzling Trial Failure
02 Sep 2025 //
FIERCE PHARMA
Merck to Present at 2025 Wells Fargo Healthcare Conference
28 Aug 2025 //
PHARMAWEB
HERTHENA-Breast04 Ph3 Starts for Patritumab Deruxtecan in Cancer
27 Aug 2025 //
BUSINESSWIRE
Merck Showcases Cardiovascular Advancements at ESC Congress 2025
25 Aug 2025 //
PHARMAWEB
BioNxt Fast-Tracks Patent for Ms Drug, Secure Autoimmune Pipeline
20 Aug 2025 //
PHARMAWEB
Enforcement Report - Week of August 20, 2025
20 Aug 2025 //
FDA
Merck, Mantro Launch Edi Membre for Alternative Protein Industry
18 Aug 2025 //
INDPHARMAPOST
Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation
18 Aug 2025 //
CONTRACTPHARMA
Merck Cuts 58 NJ Jobs in Cost-Reduction Plan
13 Aug 2025 //
FIERCE PHARMA
Padcev-Keytruda Combo Delivers Bladder Cancer `breakthrough`
13 Aug 2025 //
PRESS RELEASE
Merck to Lay Off 58 Employees at Rahway HQ
12 Aug 2025 //
BIOSPACE
Merck Had No Other Competition in Its $10 B Buyout of Verona
07 Aug 2025 //
FIERCE PHARMA
Janux Hits Clinical Milestone in Merck TRACTr Collaboration
05 Aug 2025 //
BUSINESSWIRE
